复方丹参滴丸治疗糖尿病视网膜病变的临床研究

doi:10.3969/j.issn.1671-7171.2019.01.002

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical effect of compound salvia miltiorrhiza(Danshen) pills in the treatment of diabetic retinopathy(DR). 【Methods】 The clinical data of 106 patients with DR from March 2015 to October 2017 were divided into observation group and control group with 53 cases in each group. The patients in the control group were treated with hypoglycemic, acid-base balance, and the observation group was treated with compound salvia miltiorrhiza pills on the basis of the control group. The therapeutic effect, visual field grayscale, hemangioma volume, macular area, macular thickness, serum interleukin-6 (IL-6), tumor necrosis factor (TNF-α),high sensitivity C-reactive protein (hs-CRP), plasma endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), reactive oxygen (ROS) were observed. The levels of superoxide dismutase (SOD) and malondialdehyde (MDA) (MDA) were measured by spectrophotometer.【Results】 The total effective rate was 90.57% (48 / 53) in the observation group and 77.36% (41/53) in the control group (P<0.05). The visual field grayscale, hemangioma volume, macular area, macular thickness, serum hs-CRP, IL-6,TNF-αand ET-1, VEGF, ROS, MDA levels were significantly lower in both groups than before treatment, and SOD was significantly higher than that before treatment. The improvement in the observation group was more significant than that in the control group, and the difference was statistically significant (P<0.05). There were no obvious adverse drug reactions in both groups during treatment.【Conclusion】 Compound salvia miltiorrhiza (Danshen) pills can improve the clinical efficacy, improve the symptoms of visual field defect, down-regulate the inflammatory index, improve vascular endothelial function, alleviate oxidative stress state, and the safety is good. It is worth popularizing in clinical application.

Key words： Diabetic Retinopathy/DT Pharmaceutical Preparations

Received: 13 September 2018

PACS:

R587.26

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Chuan-qiao

Cite this article:

ZHAO Chuan-qiao. Clinical Effect of Compound Danshen(Salvia Miltiorrhiza) Pills in the Treatment of Diabetic Retinopathy[J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(1): 4-7.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.01.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I1/4

[1] 韩琳娜,李一梅,谢波.复方丹参滴丸治疗非增生期糖尿病视网膜病变的研究进展[J].中成药,2015,37(2):382-384.
[2] 曾琦,段国平,杨劲松.激光治疗中度非增殖期糖尿病视网膜病变的疗效[J].医学临床研究,2015,32(9):1833-1835.
[3] 王静,朱鸿,施彩虹.糖尿病视网膜病变中内质网应激和HIF-1对VEGF的调控机制研究进展[J].上海交通大学学报(医学版),2014,30(2):240-243.
[4] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.
[5] 阮余霞,陈明,刘志谦,等.口服复方丹参滴丸联合羟苯磺酸钙治疗糖尿病患者视网膜病变的临床研究[J].中南医学科学杂志,2017,45(1):18-23.
[6] 马梦瑾,田晨光,赵志刚,等.复方丹参滴丸治疗早期糖尿病视网膜病变的疗效[J].世界中医药,2016,11(3):450-453.
[7] 吕秋菊,唐喜香,丘雅维,等.2型糖尿病视网膜病变患者外周血单个核细胞中PEDF与TNF-α水平的变化[J].中国病理生理杂志,2014,30(2):308-312.
[8] 闫锡秋,苑明茹.应用复方丹参滴丸治疗60例老年单纯性糖尿病视网膜病变疗效观察[J].时珍国医国药,2014,25(9):2187-2188.
[9] 王合作,孙燕,王少君,等.复方丹参滴丸辅助西药治疗难治性外伤性癫痫的疗效分析[J].湖南师范大学学报(医学版),2015,12(4):54-56.
[10] 杨丕坚,李舒敏,吕以培,等.复方丹参滴丸对早期糖尿病视网膜病变患者血管内皮功能的影响[J].中国实验方剂学杂志,2013,19(8):340-343.
[11] 张雪琳.糖尿病视网膜病变与相关炎性指标的临床实验检测[J].国际检验医学杂志,2016,37(24):3454-3455.
[12] 米丽芬,刘光辉,郭芳.早期糖尿病视网膜病变患者的临床特点及其治疗研究[J].临床合理用药,2017,10(1C):32-34.
[13] 王健,张凤平.前列地尔用于糖尿病肾病患者效果观察[J].山东医药,2015,2(36):107-108.
[14] 杜军辉,李蓉,刘宋芳,等.复方血栓通治疗糖尿病视网膜病变对患者氧化应激水平与视网膜中央动脉血流的影响[J].世界中西医结合杂志,2018,13(2):221-224.
[15] 夏莉莉,汤瑜斌,邵侃.前列地尔对糖尿病肾病患者血液流变学、免疫功能及MDA、SOD、ROS的影响[J].海南医学院学报,2016,22(14):1528-1531.